By Nana O 
A groundbreaking study spearheaded by researchers at NYU Langone Health and its Perlmutter Cancer Center has unveiled a promising new method for predicting the recurrence of stage III melanoma, the most aggressive form of skin cancer. The findings, published online on April 15 in the esteemed journal The Lancet Oncology, demonstrate that monitoring minuscule fragments of DNA released by dying tumor cells in the bloodstream, known as circulating tumor DNA (ctDNA), can serve as a highly accurate prognostic tool. This innovative approach holds the potential to revolutionize how oncologists identify patients at the highest risk of their disease returning, thereby enabling more personalized and timely treatment strategies.
Early Detection of Recurrence: A Critical Need in Melanoma
Melanoma, particularly in its advanced stages, poses a significant threat due to its propensity to spread. Stage III melanoma, characterized by the migration of tumor cells from the skin to nearby lymph nodes, presents a complex treatment challenge. Following the surgical removal of affected lymph nodes, detecting microscopic cancer regrowth can be exceedingly difficult with conventional imaging techniques such as X-rays and CT scans. This diagnostic gap has long fueled the search for more sensitive and early detection methods. The current study directly addresses this critical need by highlighting the predictive power of ctDNA.
Groundbreaking Findings: ctDNA as a Powerful Predictor
The research, which represents the largest assessment to date of ctDNA as a predictor for recurrence in stage III melanoma patients, involved nearly 600 men and women who had previously participated in a clinical trial for this disease. The study meticulously analyzed blood samples collected from participants across Europe, North America, and Australia. The results were striking: approximately 80% of stage III melanoma patients who exhibited detectable levels of ctDNA before commencing treatment aimed at suppressing their tumors subsequently experienced a recurrence of the disease.
Furthermore, the study revealed a direct correlation between the presence and quantity of ctDNA and the speed of recurrence. Patients with detectable ctDNA experienced disease return more than four times faster compared to those with no detectable levels of this biomarker. The higher the initial ctDNA levels, the more rapid the subsequent cancer progression.
"Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," stated study lead author Mahrukh Syeda, MS, a research scientist in the Ronald O. Perlman Department of Dermatology at NYU Grossman School of Medicine. "In the future, such assessments may be used routinely in the clinic to help guide treatment decisions."
The Evolving Landscape of ctDNA Detection During Treatment
The research team’s investigation extended beyond pre-treatment assessments, revealing significant insights into the role of ctDNA monitoring during therapy. They discovered that nearly all patients who had detectable ctDNA levels at three, six, nine, or twelve months into their treatment regimen ultimately experienced melanoma recurrence. This finding is particularly crucial, as it suggests that the appearance of ctDNA in patients who initially tested negative prior to therapy could be an early warning sign that the disease is worsening or has returned, even if not yet visible on standard imaging.
Understanding Circulating Tumor DNA (ctDNA)
The ctDNA method functions by targeting specific, common mutations found in the genetic code of melanoma cells. As these tumor cells break down, they release fragments of their mutated DNA into the surrounding bloodstream. These fragments, or ctDNA, can then be detected and quantified through sophisticated laboratory analyses. This non-invasive blood test offers a direct window into the presence and activity of cancer cells throughout the body.
A Growing Body of Evidence for ctDNA’s Utility
The current study builds upon a robust foundation of prior research that has established the efficacy of ctDNA tests in tracking the progression of various cancers, including colorectal and breast cancers. Notably, in 2021, the same research team from NYU Langone Health had demonstrated that higher ctDNA levels in patients with stage IV melanoma – a more disseminated form of the disease that has spread throughout the body – were associated with poorer survival outcomes. They also found that changes in ctDNA measurements over the course of treatment could effectively stratify patients into groups with better or worse prognoses.
The Lancet Oncology publication marks a significant advancement by being the most extensive study to date to specifically evaluate ctDNA as a predictor of recurrence in stage III melanoma.
Rigorous Methodology and Robust Analysis
The study’s comprehensive nature is underscored by its rigorous methodology. The research team meticulously compared ctDNA measurements with clinical evidence of cancer recurrence. Their statistical analysis was designed to account for a range of factors that could independently influence recurrence, such as a patient’s sex, age, and the specific type of therapy administered. This careful approach ensures that the observed correlations are attributable to the predictive power of ctDNA itself, rather than confounding variables.
ctDNA Outperforms Traditional Biomarkers
Perhaps one of the most compelling findings of the study is that assessing ctDNA levels proved to be as effective, and in some instances superior, to other experimental tests that examine the tumor tissue itself. These comparative tests include those that measure the immune activity within a group of cancer cells.
"Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear, direct measure of the disease itself and can tell us outright that melanoma has returned," explained study senior author and dermatologist David Polsky, MD, PhD. Dr. Polsky holds the esteemed position of the Alfred W. Kopf, M.D., Professor of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology at NYU Langone Health.
Addressing Limitations and Future Directions
While the study presents a highly optimistic outlook for ctDNA in melanoma management, Dr. Polsky acknowledged a crucial caveat: in some instances, cancer recurrence occurred even in patients who had initially tested negative for ctDNA before commencing therapy. This observation highlights the ongoing need for refinement and improvement of diagnostic technologies.
"To address this, the authors next plan to improve the sensitivity of their test," Dr. Polsky added. He is also a professor in NYU Grossman School of Medicine’s Department of Pathology. The research team is committed to further clinical investigation to determine whether leveraging ctDNA for treatment decision-making can demonstrably enhance patient survival rates and improve their overall quality of life.
Broader Implications for Cancer Care
The implications of this research extend beyond stage III melanoma. As ctDNA detection technology advances, its potential applications in monitoring other cancer types, predicting treatment response, and guiding therapeutic interventions are likely to expand. This shift towards a more molecularly driven approach to cancer management promises a future where treatment is not only more effective but also tailored to the individual patient’s disease profile, minimizing unnecessary toxicity and maximizing therapeutic benefit.
Collaboration and Funding
This pivotal study was made possible through the collaborative efforts of a multidisciplinary team of researchers from various institutions and was supported by funding from Novartis Pharmaceuticals Corporation. The extensive list of contributors underscores the global commitment to advancing cancer research and patient care.
The involvement of Dr. Polsky in advisory boards and receiving honoraria and research contracts from pharmaceutical companies, including Novartis and Merck, is disclosed in accordance with NYU Langone Health’s policies and procedures, ensuring transparency in research conduct.
The research team included Jennifer Wiggins-Crosby, PhD, and Saim Ali, BA, from NYU Langone Health. International collaborators included Georgina Long, MD, PhD, from the University of Sydney, Australia; James Garrett, PhD, from Novartis Pharmaceuticals Corporation; Victoria Atkinson, MD, from the University of Queensland, Australia; Mario Santinami, MD, from the National Cancer Institute of Milan, Italy; Dirk Schadendorf, MD, from the University of Duisburg-Essen, Germany; Axel Hauschild, MD, from the University Hospital, Campus Kiel, Germany; Michael Millward, MD, from the University of Western Australia; Mario Mandala, MD, from the University of Perugia, Italy; Vanna Chiarion-Sileni, MD, from the Veneto Institute of Oncology, Italy; Michael Smylie, MD, from the Cross Cancer Institute, Canada; Georgy Manikhas, MD, from St. Petersburg Oncology Hospital, Russia; Reinhard Dummer, MD, from the University Hospital Zurich Skin Cancer Center, Switzerland; Sachin Bajirao Adnaik, PhD, from Novartis Healthcare Pvt. Ltd., India; and Monique Tan, MD, MPH, and Maya Dajee, PhD, from Novartis Pharmaceuticals. This wide-reaching collaboration highlights the international significance of this research.
The Future of Melanoma Management
The findings presented by the NYU Langone Health team represent a significant leap forward in the fight against melanoma. By harnessing the power of ctDNA, oncologists may soon possess a more precise and timely tool to identify patients at high risk of recurrence, enabling proactive interventions and ultimately improving outcomes for individuals battling this challenging disease. The ongoing pursuit of enhanced test sensitivity and the exploration of its clinical utility promise to further solidify ctDNA’s role as a cornerstone of personalized cancer medicine.
